Moleculin Biotech Publishes Cardiac Safety Analysis of Annamycin

What Happened
Moleculin Biotech, Inc. (MBRX) announced by press release dated September 28, 2026 (filed on Form 8‑K) that a peer‑reviewed analysis of the cardiac safety of Annamycin (L‑Annamycin, also called naxtarubicin) was published in Frontiers in Cardiovascular Medicine. The paper, titled “Cardiac safety of L‑Annamycin: a pooled analysis of five clinical trials,” reports cardiac safety findings from 90 patients treated across five clinical trials in acute myeloid leukemia (AML) and metastatic soft tissue sarcoma (STS). A copy of the press release was included as Exhibit 99.1 to the 8‑K.

Key Details

• Publication: Frontiers in Cardiovascular Medicine; title: “Cardiac safety of L‑Annamycin: a pooled analysis of five clinical trials.”
• Patient pool: 90 patients evaluated across five clinical trials.
• Indications studied: acute myeloid leukemia (AML) and metastatic soft tissue sarcoma (STS).
• Filing: Press release dated September 28, 2026; attached to the company’s Form 8‑K as Exhibit 99.1.

Why It Matters
Cardiac safety is a central concern for anthracycline‑class cancer drugs; a peer‑reviewed pooled analysis addressing cardiac effects provides independent, scientific visibility into Annamycin’s safety profile. For investors, publication may affect clinical development perception, potential regulatory discussions, and partner or investor interest by documenting safety data across multiple trials. The 8‑K simply discloses the publication and press release; it does not announce new financial results or changes in management.